ClinicalTrials.gg
CompletedNCT05040672LB2008Updated Aug 2, 2022

Evaluation of Knowledge and Practice About Prostate Cancer in Male Employees

An observational study in Prostate Cancer, sponsored by Libbs Farmacêutica LTDA. Completed at 1 site in Brazil. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-02.

Sponsored by Libbs Farmacêutica LTDA · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
280
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 134 studies in Prostatic Neoplasms with a site in Brazil — 24 open to participants now, 54 under way, 31 of them phase 3. Prostatic Neoplasms · Brazil.

Enrollment
11th of 18
280 · median 341
Started
2021
with 5 others
Observational
18 of 134
3 open now
Registered
93rd of 134
by date

Among the 134 studies in Prostatic Neoplasms with a site in Brazil, this one is the 11th largest by enrollment of the 18 observational ones that give a count, is one of 6 that started in 2021, is one of 18 observational ones, and was the 93rd registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

24 of the 134 studies in Prostatic Neoplasms with a site in Brazil are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 134 studies in Prostatic Neoplasms with a site in Brazil, or all of them as a file.
02

Study summary

Analyze, through an online questionnaire, the knowledge and practice about the prevention and detection of prostate cancer in male employees of a pharmaceutical company.

Read the detailed description

In Brazil, there are still few published and current studies that explore man's attention and awareness of health. Historically, women attend medical appointments and perform routine tests more frequently than men. For this is very important Analyze, through an online questionnaire, the knowledge and practice about the prevention and detection of prostate cancer in male employees of Libbs Farmacêutica (a pharmaceutical company in Brazil).

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

As this is a non-probabilistic or convenience (non-random) sampling, the sample size calculation is not applicable. Today there are about 1500 male employees at Libbs Pharmaceuticals and all will be invited to participate in the survey. Answers obtained from all questionnaires filled in their entirety will be included for analysis.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male individuals included in the Libbs workforce;
  • Age 18 years or older;
  • Subjects who agree to participate in the study after reading and signing the Form.

Exclusion criteria

Exclusion Criteria:

  • There is no exclusion criteria
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
280 participants (actual)
Patient registry
No

Groups and cohorts

  • Group I

    All volunteer male employees of Libbs Pharmaceuticals residing in all Brazilian regions will participate in this research.An online questionnaire will be applied to assess research subjects understanding of prostate cancer and health habits.

    Behavioral: questionare online application

Interventions

  • Behavioralquestionare online application

    questionare online application

06

What researchers measure

Primary outcomes

  1. Evaluation of Knowledge and Practice About Prostate Cancer e Healthy Habits

    Assess the subjects knowledge and practice in relation to educational campaigns aimed at prostate cancer.All the information wil be collected using a questionnaire previously approved by the ethics committee.

    Time frame: 1 month

07

Study locations

1 site
  • Augusto Figueiredo
    São Paulo, 01140050, Brazil
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Jul 2022, 13 months.

Of 109 industry-sponsored observational studies under Prostatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 65. This study's 13 months is below that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2021
First posted
Sep 10, 2021
StartActual
Jun 1, 2021
Primary completionActual
Jul 29, 2022
CompletionActual
Jul 29, 2022
Last update
Aug 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05040672
Lead sponsor
Libbs Farmacêutica LTDA
Responsible party
Sponsor
First posted
Sep 10, 2021
Start date
Jun 1, 2021
Primary completion
Jul 29, 2022
Completion
Jul 29, 2022
Last update
Aug 2, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion